Vertex Pharmaceuticals Inc (VRTX) Stock Price

VRTXStock
$552.85+38.59%52W
Market Cap$140.13B
P/E34.21x
PEG Ratio1.91
Div yield
Beta0.26

VRTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)5.19%
Price vs S&P 500 (4W)8.61%
PEG Ratio1.91
VGM Score54.48
P/E Ratio (Annual)34.21x

VRTX Earnings Surprise History

Q2 254.52est. 4.25
Q3 254.80est. 4.58
Q4 255.03est. 5.15
Q1 264.47est. 4.31
Q2 264.73est. 4.75

VRTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.10
4.10
4.10
4.05

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
VRTXVertex Pharmaceuticals Inc
DCB$552.85
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
BMYBristol-Myers Squibb Co.BBB$67.92

About Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals is a global biotech company with a dominant position in cystic fibrosis treatments (Kalydeco, Orkambi, Symdeko, Trikafta, and Alyftrek) and a diversified pipeline including approved gene-editing therapy Casgevy for blood disorders and Journavx for acute pain. The company is also advancing cell therapies for type 1 diabetes and small-molecule programs targeting APOL1-mediated kidney disease.